Avidity Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

San diego , april 22, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that on april 20, 2024, the human capital management committee of avidity's board of directors granted non-qualified stock option awards to purchase an aggregate of 37,500 shares of its common stock and 18,750 restricted stock units ("rsus") to three (3) new non-executive employees under the avidity biosciences, inc. 2022 employment inducement incentive award plan (the "2022 inducement plan"). the awards were granted as inducements material to the employees entering into employment with avidity in accordance with nasdaq listing rule 5635(c)(4).

San diego , march 27, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that avidity management will be participating in the following upcoming conferences: cantor fitzgerald virtual muscular dystrophy symposium on april 3 at 9:40 a.m. pt/ 12:40 p.m.

San diego , march 21, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that on march 20, 2024, the human capital management committee of avidity's board of directors granted non-qualified stock option awards to purchase an aggregate of 30,800 shares of its common stock and 15,400 restricted stock units ("rsus") to three (3) new non-executive employees under the avidity biosciences, inc. 2022 employment inducement incentive award plan (the "2022 inducement plan"). the awards were granted as inducements material to the employees entering into employment with avidity in accordance with nasdaq listing rule 5635(c)(4).

San diego , feb. 29, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced its support for rare disease day®, highlighting the importance of bringing awareness to the devastating impact rare diseases have on patients, families and caregivers worldwide. "today, on rare disease day, we are proud to join the global community in raising awareness for people living with rare diseases," said sarah boyce, president and chief executive officer at avidity.

Funding from new and existing investors, including adage capital partners lp, boxer capital, casdin capital, llc, farallon, janus henderson investors, ra capital management, rtw investments, wellington management, as well as multiple large investment management firms pro forma cash, cash equivalents and investments expected to provide runway into late 2026 avidity to host volume 8 of investor and analyst event series via webcast march 4, 2024, at 8:00 a.m. et to present  aoc 1001 data from marina-ole™ san diego , feb. 29, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that it has agreed to sell 15,224,773 shares of its common stock at a price of $16...

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.88 per share a year ago.

Avidity Biosciences, Inc. (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.

Avidity Biosciences (NASDAQ: RNA ) stock is soaring in early trading after the company disclosed that it had expanded its partnership with a huge drugmaker, Bristol Myers Squibb (NYSE: BMY ). More About the RNA-BMY Deal Avidity and Bristol-Myers will increase the number of Antibody Oligonucleotide Conjugates (AOCs) on which they will collaborate in an effort to develop new cardiovascular treatments.

Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.

Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co (NYSE:BMY).  The pact is focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.

Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potential to earn up to $2.2 billion in milestone payments. The news sent Avidity's stock up 21% in premarket trade.

SAN DIEGO , Aug. 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following upcoming conferences: 2023 Wells Fargo Healthcare Conference on September 6 at 5:45 a.m. PT/8:45 a.m.

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.71 per share a year ago.